Washington, DC 20006-5349
HELPLINE
Despite initial positive signs from its phase 2 counterpart, the phase 3 LUME-Meso trial in malignant pleural mesothelioma did not meet its primary endpoint of…
On Tuesday, November 13, we hosted our Meet the Mesothelioma Experts live broadcast with Dr. Marjorie Zauderer, of Memorial Sloan Kettering Cancer Center and chair…
UPDATE: This study has been completed with the full analysis of all 54 patients. Click here for full results. Earlier this month, during the most…
Yesterday, at the annual meeting of the American Society of Gene and Cell Therapy in Chicago, researchers from Memorial Sloan Kettering Cancer Center released a…
It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim,…
UPDATE: Aduro Biotech announced on December 12 that they have decided to discontinue its CRS-207 clinical trial and wind down each of its trials in mesothelioma.…
The World Conference on Lung Cancer is a prestigious annual event organized by the International Association for the Study of Lung Cancer (IASLC). The conference,…
In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to…
“There’s no question that research cures cancer,” began Dr. Rich Alexander of the University of Maryland and chair of the Meso Foundation’s Board of Directors.…
Dr. Raffit Hassan of the National Cancer Institute, and former chair of the Mesothelioma Applied Research Foundation’s Science Advisory Board, announced results of the Phase…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
